Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reata Hopes To Beat Competition To Market With Abbott Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Reata Pharmaceuticals hopes the strength of its partnerships and intellectual property will allow it to get an edge on a hot market.

You may also be interested in...

Abbott Spin-Off AbbVie To Remain Close To Its Roots

Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts